For neutrophils, rather than simply depleting them, reprogramming N2 neutrophils toward the N1 anti-tumor phenotype via IFN-β or TGF-β blockade may better align with safety requirements in the CNS. The gene discussed is TGFB1; the disease is neoplasm.